Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17273432 | 0.93 | PTPN11 (0.42) | JAK2JAK3PTK2PTPN11WNT3A | |
| SCHEMBL17273417 | 0.93 | PTPN11 (0.41) | JAK2JAK3PTK2PTPN11WNT3A | |
| SCHEMBL15556354 | 0.92 | JAK2 (0.40) | JAK2JAK3PTK2PTPN11WNT3A | |
| SCHEMBL17273489 | 0.90 | JAK2 (0.40) | JAK2JAK3PTK2PTPN11WNT3A | |
| SCHEMBL17273366 | 0.90 | ALK (0.44) | JAK2JAK3PTK2PTPN11WNT3A | |
| SCHEMBL17273392 | 0.90 | PTPN11 (0.41) | JAK2JAK3PTK2PTPN11WNT3A | |
| SCHEMBL17273503 | 0.89 | PTPN11 (0.43) | JAK2JAK3PTK2PTPN11WNT3A | |
| SCHEMBL15555940 | 0.85 | PTPN11 (0.39) | PTPN11GPR119TP53MAPT | |
| SCHEMBL15557440 | 0.84 | GPR119 (0.41) | JAK2JAK3PTK2PTPN11GPR119 | |
| SCHEMBL17273313 | 0.84 | MEN1 (0.46) | PTPN11WNT3AGPR119TP53CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353107-B2 | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K6 | JAK2 86/4885JAK3 77/4885PTK2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.